Navigation Links
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
Date:10/11/2011

LONDON, October 12, 2011 /PRNewswire/ --

- Two pivotal trials initiated for treatment of iron deficiency anaemia associated with ulcerative colitis and Crohn's disease -

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease (IBD).

"Following our successful fundraising in June, we are delighted to have now treated the first patients in the AEGIS Phase 3 programme and we remain on course to have top line results from these studies in late 2012.  Effective treatment of IDA represents a very attractive commercial opportunity and the start of recruitment is an important milestone for Shield Therapeutics as we continue the rapid development of ST10 to address this significant unmet need for the many patients with IDA." said Carl Sterritt, Chief Executive Officer and Co-Founder of Shield Therapeutics.

ST10 is an oral ferric iron-based pharmaceutical that can be administered to patients with improved tolerability compared to currently marketed oral iron treatments and also does not carry the risk of hypersensitivity reactions as is the case with currently marketed intravenous iron therapies.  Whilst prescribers often try oral ferrous products as first line therapy, many subjects prove intolerant and suffer from continuously occurring side effects, exacerbation of inflammatory lesions and failure to correct iron deficiency.  This results in the need for expensive, complicated and invasive intravenous iron therapy.  When treated with ST10, the total dose exposure of unabsorbed iron within the gastrointestinal tr
'/>"/>

SOURCE Shield Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
2. TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical
3. vProtect(TM) Luminal Shield Stabilizes Life-Threatening Plaque
4. SyntheMed Announces FDA Clearance of SinusShield(TM)
5. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
6. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
7. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
8. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
9. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
10. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
11. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
(Date:1/14/2014)... Washington, DC (PRWEB) January 14, 2014 ... session for Thursday, January 23, 2014 at 2pm EST ... Actionable Knowledge.” The topic focuses on how technology can ... mission critical decisions for government agencies. The online webinar ...
(Date:1/14/2014)... The largest international professional organization of scientists ... derivatives thereof has endorsed an educational program that ... challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural Product ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... North ... America, DEERFIELD, Ill., ... Cartago, Costa Rica has been,recognized with the 2008 Shingo Prize for Operational ... North America,-- is being honored for its achievements in driving higher quality ...
... announced today it,submitted to the U.S. Food & ... Application (BLA) for motavizumab, an investigational,monoclonal antibody (MAb) ... supported by clinical trial data from more than ... of serious disease,caused by respiratory syncytial virus (RSV) ...
... Unique and Innovative Formulation Available Without a ... Prescription ... today announced the,launch of PSORENT, a clinically proven, steroid-free, ... which has,proven efficacy against psoriasis symptoms, in a novel, ...
Cached Biology Technology:Baxter's Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing 2MedImmune Submits Biologics License Application to FDA for Motavizumab 2MedImmune Submits Biologics License Application to FDA for Motavizumab 3NeoStrata(R) Announces the Launch of PSORENT(TM) Psoriasis Topical Treatment 2
(Date:4/22/2014)... Winsor Lowe, interim director of the University of Montana,s ... in the Proceedings of the National Academy of Sciences ... network. , ... the U.S. Geological Survey, the University of Washington, the Cary ... U.S. Forest Service Northern Research Station examined 664 water samples ...
(Date:4/22/2014)... Scientists at the University of Massachusetts Amherst and the ... week report that they have discovered a new genus ... the Negro River in the Amazonia State of Brazil. ... Adlia Nogueira and Jos Antnio Alves-Gomes of INPA, describe ... the journal Proceedings of the Natural Sciences of ...
(Date:4/22/2014)... Mass. Analyzing thousands of breeding bird surveys sent ... and Canada over 35 years, wildlife researchers report that ... either northward or toward higher elevation in response to ... This means that most previous studies of potential climate ... factor or the other have likely underestimated the effects ...
Breaking Biology News(10 mins):New research focuses on streamwater chemistry, landscape variation 2New electric fish genus and species discovered in Brazil's Rio Negro 2Wildlife response to climate change is likely underestimated, experts warn 2
... 2011 Reportlinker.com announces that a new ... catalogue: Global Biometrics Industry ... This report analyzes the worldwide markets ... the following Technologies: AFIS (Automated Fingerprint Identification ...
... CA ---- Researchers at the Salk Institute for Biological Studies ... potentially cure sickle cell disease and many other disorders caused ... The technique uses cells from a patient,s skin to ... developing into various types of mature tissues -- including blood. ...
... the endowments of genes in other animals and plants are like ... a genetic sense introduces an element of variety and surprise that ... in a review of more than 100 studies on the topic ... and colleagues focus on cytosine, one of the four chemical "bases" ...
Cached Biology News:Global Biometrics Industry 2Global Biometrics Industry 3Global Biometrics Industry 4Global Biometrics Industry 5Global Biometrics Industry 6Global Biometrics Industry 7Global Biometrics Industry 8Global Biometrics Industry 9Global Biometrics Industry 10Global Biometrics Industry 11Global Biometrics Industry 12Global Biometrics Industry 13Global Biometrics Industry 14Global Biometrics Industry 15Global Biometrics Industry 16Global Biometrics Industry 17Global Biometrics Industry 18Global Biometrics Industry 19Global Biometrics Industry 20Global Biometrics Industry 21Global Biometrics Industry 22Global Biometrics Industry 23Global Biometrics Industry 24Salk researchers develop safe way to repair sickle cell disease genes 2Salk researchers develop safe way to repair sickle cell disease genes 3Salk researchers develop safe way to repair sickle cell disease genes 4
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
... FbxL7 The F box, named ... was originally observed, is an approximately ... F-box proteins are components of modular ... (SKP1, cullin, F-box proteins), which function ...
Rabbit polyclonal to SERHL ( Abpromise for all tested applications). entrezGeneID: 94009 SwissProtID: Q9H4I8...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Biology Products: